Cisplatin resistance and opportunities for precision medicine
- PMID: 26804248
- DOI: 10.1016/j.phrs.2016.01.001
Cisplatin resistance and opportunities for precision medicine
Abstract
Cisplatin is one of the most commonly used chemotherapy drugs, treating a wide range of cancer types. Unfortunately, many cancers initially respond to platinum treatment but when the tumor returns, drug resistance frequently occurs. Resistance to cisplatin is attributed to three molecular mechanisms: increased DNA repair, altered cellular accumulation, and increased drug inactivation. The use of precision medicine to make informed decisions on a patient's cisplatin resistance status and predicting the tumor response would allow the clinician to tailor the chemotherapy program based on the biology of the disease. In this review, key biomarkers of each molecular mechanism will be discussed along with the current clinical research. Additionally, known polymorphisms for each biomarker will be discussed in relation to their influence on cisplatin resistance.
Keywords: ABC transporters; Cisplatin resistance; Copper transporters; ERCC1; Glutathione; Nucleotide excision repair.
Published by Elsevier Ltd.
Similar articles
-
Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.Radiol Oncol. 2019 Mar 28;53(2):148-158. doi: 10.2478/raon-2019-0018. Radiol Oncol. 2019. PMID: 30956230 Free PMC article. Review.
-
Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?Cancer Lett. 2014 May 1;346(2):163-71. doi: 10.1016/j.canlet.2014.01.005. Epub 2014 Jan 21. Cancer Lett. 2014. PMID: 24462818 Review.
-
Cisplatin: The first metal based anticancer drug.Bioorg Chem. 2019 Jul;88:102925. doi: 10.1016/j.bioorg.2019.102925. Epub 2019 Apr 11. Bioorg Chem. 2019. PMID: 31003078 Review.
-
Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19. Lung Cancer. 2009. PMID: 18804893 Review.
-
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.Drug Resist Updat. 2016 Sep;28:65-81. doi: 10.1016/j.drup.2016.07.001. Epub 2016 Jul 16. Drug Resist Updat. 2016. PMID: 27620955 Review.
Cited by
-
LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma.Onco Targets Ther. 2020 Sep 22;13:9333-9348. doi: 10.2147/OTT.S244879. eCollection 2020. Onco Targets Ther. 2020. Retraction in: Onco Targets Ther. 2023 Jul 19;16:615-616. doi: 10.2147/OTT.S430432 PMID: 33061421 Free PMC article. Retracted.
-
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.Cell Death Dis. 2022 Sep 27;13(9):826. doi: 10.1038/s41419-022-05257-y. Cell Death Dis. 2022. PMID: 36163324 Free PMC article.
-
Resistance to the platinum‑based chemotherapeutic drugs in oral cancer: Focus on the role of p22phox (Review).Biomed Rep. 2024 Oct 3;21(6):182. doi: 10.3892/br.2024.1870. eCollection 2024 Dec. Biomed Rep. 2024. PMID: 39420922 Free PMC article. Review.
-
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.Molecules. 2022 Apr 11;27(8):2466. doi: 10.3390/molecules27082466. Molecules. 2022. PMID: 35458666 Free PMC article. Review.
-
Review about Powerful Combinations of Advanced and Hyphenated Sample Introduction Techniques with Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) for Elucidating Trace Element Species in Pathologic Conditions on a Molecular Level.Int J Mol Sci. 2022 May 29;23(11):6109. doi: 10.3390/ijms23116109. Int J Mol Sci. 2022. PMID: 35682788 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
